FULC · Fulcrum Therapeutics, Inc. · Proposed Sales
$3.69
+0.01 (+0.27%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$285.35M
Shares
76.30M
Volume · Oct 2
1.54M
Avg daily vol (3M)
1.59M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-09-02 | Greg Tourangeau | former officer | 14,062 | 2026-09-02 | Merrill Lynch, Pierce, Fenner & Smith Inc |
| 2026-06-26 | ALAN EZEKOWITZ | Director | 18,000 | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | CURTIS G OLTMANS | Officer | 3,452 | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-08 | RA Capital Healthcare Fund LP | 10% Stockholder | 4,175,139 | 2025-12-08 | BTIG, LLC |
| 2025-11-19 | ROBERT J GOULD | Director | 45,000 | 2025-11-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2024-03-08 | Greg Tourangeau | Officer | 4,884 | 2024-03-08 | Merrill Lynch, Pierce, Fenner & Smith Inc |
Showing 1–6 of 6 filings